WASHINGTON: Positive outcomes from a novel treatment for locally advanced rectal cancer include the occasional full avoidance of surgery. The chance of a recurrence is also decreased.
According to a thorough study done at Uppsala University and published in eClinicalMedicine, the approach is beneficial.
“The tumour disappears completely more often, thereby increasing the chance of avoiding surgery and retaining normal rectum and rectal function.Moreover, there are fewer metastases,” said Bengt Glimelius, Professor of Oncology at Uppsala University and Senior Consultantat Uppsala University Hospital, about the new method.
Rectal cancer affects around 2,000 people in Sweden every year. Of these, a third have a high risk of recurrence. When a person is diagnosed with rectal cancer, part of the bowel is often removed, which could lead to the need for a stoma or problems controlling one’s bowels. Patients often first receive radiotherapy or a combination of radiotherapy and concurrent chemotherapy for five weeks, followed by surgery and usually an additional round of chemotherapy for up to six months.
A study conducted by Uppsala University in everyday healthcare shows that it is possible to double the chance of eliminating the need to surgically remove part of the bowel if all radiotherapy and chemotherapy are given first and then the patient undergoes surgery, if necessary.
“If the tumour disappears completely during treatment, surgery is not required. This means that the rectum is preserved and the need for a stoma and a new rectum is eliminated. When part of the rectum is surgically removed, the new rectum does not quite understand that it should be able to refrain from frequently sending a signal to the brain that you need to use the toilet,” said Bengt Glimelius.
A large number of doctors, researchers and research nurses have contributed to the study. Patient data was collected for a large number of patients via the Swedish Colorectal Cancer Registry (SCRCR), with 461 patients included.
Locally advanced rectal cancer has traditionally been treated with a combination of radiotherapy and chemotherapy, followed by surgery and further chemotherapy. Four years ago, a randomised study showed that an alternative approach of one week of radiotherapy followed by just over four months of chemotherapy resulted in more tumours disappearing completely and fewer having distant metastases. Later on, however, slightly more local recurrences were observed. Uppsala was the first region to choose to introduce this treatment, but with a shortened chemotherapy period of three months. Several other regions later followed suit.
The new study confirms the results of the previous randomised study, but also that the noted increase in local recurrences was not observed here.
“With the old treatment, the randomised study failed to find any tumour in 14 percent of patients who underwent surgery. The new model doubled that figure to 28 per cent. The new Swedish study had the same results, but without an increase in local recurrence rate after almost five years of follow-up. It is important to show that experimental treatments also work in everyday healthcare,” said Bengt Glimelius.
According to a thorough study done at Uppsala University and published in eClinicalMedicine, the approach is beneficial.
“The tumour disappears completely more often, thereby increasing the chance of avoiding surgery and retaining normal rectum and rectal function.Moreover, there are fewer metastases,” said Bengt Glimelius, Professor of Oncology at Uppsala University and Senior Consultantat Uppsala University Hospital, about the new method.
Rectal cancer affects around 2,000 people in Sweden every year. Of these, a third have a high risk of recurrence. When a person is diagnosed with rectal cancer, part of the bowel is often removed, which could lead to the need for a stoma or problems controlling one’s bowels. Patients often first receive radiotherapy or a combination of radiotherapy and concurrent chemotherapy for five weeks, followed by surgery and usually an additional round of chemotherapy for up to six months.
A study conducted by Uppsala University in everyday healthcare shows that it is possible to double the chance of eliminating the need to surgically remove part of the bowel if all radiotherapy and chemotherapy are given first and then the patient undergoes surgery, if necessary.
“If the tumour disappears completely during treatment, surgery is not required. This means that the rectum is preserved and the need for a stoma and a new rectum is eliminated. When part of the rectum is surgically removed, the new rectum does not quite understand that it should be able to refrain from frequently sending a signal to the brain that you need to use the toilet,” said Bengt Glimelius.
A large number of doctors, researchers and research nurses have contributed to the study. Patient data was collected for a large number of patients via the Swedish Colorectal Cancer Registry (SCRCR), with 461 patients included.
Locally advanced rectal cancer has traditionally been treated with a combination of radiotherapy and chemotherapy, followed by surgery and further chemotherapy. Four years ago, a randomised study showed that an alternative approach of one week of radiotherapy followed by just over four months of chemotherapy resulted in more tumours disappearing completely and fewer having distant metastases. Later on, however, slightly more local recurrences were observed. Uppsala was the first region to choose to introduce this treatment, but with a shortened chemotherapy period of three months. Several other regions later followed suit.
The new study confirms the results of the previous randomised study, but also that the noted increase in local recurrences was not observed here.
“With the old treatment, the randomised study failed to find any tumour in 14 percent of patients who underwent surgery. The new model doubled that figure to 28 per cent. The new Swedish study had the same results, but without an increase in local recurrence rate after almost five years of follow-up. It is important to show that experimental treatments also work in everyday healthcare,” said Bengt Glimelius.
